Loading...
01/11 08:24
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects strong financial performance with raised revenue and EBITDA guidance, a solid productivity plan, and promising product developments like Cologuard Plus and Cancerguard. The Q&A section highlights ongoing payer negotiations and future growth potential, despite some uncertainties in timelines and pricing strategies. The overall sentiment is positive, supported by optimistic guidance and strategic initiatives aimed at long-term growth.
Total Revenue $851 million, a 20% year-over-year increase. This growth was driven by Cologuard's strong brand awareness, commercial execution, health systems integrations, and a record number of ordering providers.
Screening Revenue $666 million, a 22% year-over-year increase. Growth was led by broad-based Cologuard growth, care gap programs, and rescreens.
Precision Oncology Revenue $183 million, a 12% year-over-year increase on a core basis. Growth was driven by Oncotype DX expansion internationally, U.S. Oncotype DX volumes, and partner revenues.
Adjusted EBITDA $135 million, a 37% year-over-year increase. Adjusted EBITDA margins expanded by 200 basis points to 16%, driven by efficiency efforts across lab, supply chain, G&A, and support functions.
Non-GAAP Gross Margins 71%, down 100 basis points year-over-year. The reduction was due to record care gap shipments causing a temporary timing difference between cost of goods and revenue.
Free Cash Flow $190 million, a $77 million increase year-over-year. This was driven by increased receivables collections following the Cologuard Plus launch and working capital improvements.
Year-to-Date Free Cash Flow $236 million, a $173 million or 270% year-over-year increase. This was attributed to improved receivables collections and working capital improvements.
Cash and Securities Just over $1 billion at the end of the quarter.
Cancerguard launch: Introduced Cancerguard, a multi-cancer early detection test screening for over 50 cancer types and subtypes. Leveraging multiple channels for adoption, including primary care physicians, health systems, and a consumer-initiated ordering platform. Direct-to-consumer marketing campaigns initiated.
Cologuard Plus: Expanded access to Cologuard Plus with positive coverage decisions from top 10 payers. Demonstrated 95% sensitivity and 94% specificity, reducing false positives by 40% compared to the original Cologuard.
Oncodetect: Launched MRD test Oncodetect, showing encouraging utilization in colorectal and breast cancer.
Cologuard brand awareness: Achieved over 90% consumer recognition, driving adoption among 55 million Americans not up-to-date with colorectal cancer screening.
Precision Oncology expansion: Oncotype DX saw international growth and expanded screening guidelines to younger age groups.
Revenue growth: Total revenue grew 20% year-over-year to $851 million, with screening revenue up 22% and Precision Oncology revenue up 12%.
Adjusted EBITDA: Increased 37% year-over-year to $135 million, with margins expanding by 200 basis points to 16%.
Free cash flow: Increased to $190 million, up $77 million year-over-year, driven by receivables collections and working capital improvements.
Consumer-initiated orders (CIO): Enabled individuals to request tests online via telehealth, driving triple-digit growth in this demographic.
R&D investments: Focused on multi-omic platform advancements, including liver, esophageal, and endometrial cancer tests. Presented ONCOGUARD liver data and planned further clinical validation studies for MRD tests.
Non-GAAP gross margins: Gross margins decreased by 100 basis points compared to the previous year, driven by record care gap shipments. This indicates potential cost pressures and timing mismatches between costs and revenue.
Freenome licensing agreement: The upfront payment of $75 million for the Freenome licensing agreement will be expensed to R&D upon clearance of HSR, which could impact short-term financials and adjusted EBITDA.
Cologuard rescreens: Rescreens now represent more than 25% of total screening volume, but maintaining this recurring revenue stream requires consistent patient engagement and trust in the product.
Cancerguard launch: The launch of Cancerguard, a multi-cancer early detection test, involves significant investment in direct-to-consumer marketing and training of sales teams, which could strain resources and require time to achieve profitability.
Pipeline investments: Investments in R&D for new tests like Oncodetect and ONCOGUARD liver require substantial funding and carry risks related to clinical validation, regulatory approval, and market adoption.
Precision Oncology portfolio: While showing positive momentum, the portfolio's growth depends on effective commercial execution and adoption of new products like Oncodetect, which may face competitive and market challenges.
Full Year 2025 Revenue Guidance: Raised to between $3.22 billion and $3.235 billion, reflecting an increase of $78 million at midpoint.
Screening Revenue Guidance: Expected to be between $2.51 billion and $2.52 billion, representing 20% growth at midpoint.
Precision Oncology Revenue Guidance: Projected to be between $710 million and $715 million, reflecting 9% growth at midpoint.
Adjusted EBITDA Guidance: Increased to between $470 million and $480 million for the full year, implying 47% growth and 300 basis points of margin expansion.
Cancerguard Launch and Adoption: The multi-cancer early detection test, Cancerguard, was launched in Q3 2025. Plans include training the entire U.S. commercial team by year-end and investing in direct-to-consumer marketing starting in Q4 2025.
Oncodetect Development: Clinical validation data for the next-generation version of Oncodetect leveraging MAESTRO technology is expected in 2026.
MRD Evidence Generation: Over 10 clinical validation studies planned over the next few years, including 4 key studies in breast cancer, colorectal cancer, and pan-tumor indications.
Oncoguard Liver Test: Data from the ALTUS study to be presented at the American Association for the Study of Liver Diseases meeting, highlighting its potential for liver cancer surveillance.
The selected topic was not discussed during the call.
The earnings call reflects strong financial performance with raised revenue and EBITDA guidance, a solid productivity plan, and promising product developments like Cologuard Plus and Cancerguard. The Q&A section highlights ongoing payer negotiations and future growth potential, despite some uncertainties in timelines and pricing strategies. The overall sentiment is positive, supported by optimistic guidance and strategic initiatives aimed at long-term growth.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
